Pharma Companies

Licences of 18 pharma firms cancelled for manufacturing spurious drugs

In a major crackdown against the manufacture of substandard drugs, central and state regulators conducted joint inspections at 76 pharma companies and cancelled the licences of 18 of them for producing spurious and adulterated drugs, official sources said on Tuesday. The inspections were carried out across 20 states and Union territories in the past 15 days, they said. A source said that the action has been taken against 76 companies in the first phase of a special drive against the manufacture of substandard drugs. "Licences of 18 pharma companies have been cancelled for manufacturing spurious and adulterated drugs and for violating GMP (good manufacturing practice).... Besides, 26 firms have been given show-cause notices," an official source said. The sources said that as part of the special drive, the regulators have identified 203 firms. A majority of the companies are from Himachal Pradesh (70), followed by Uttarakhand (45) and Madhya Pradesh (23). Recently, questions have b

Budget backs pharma R&D, nursing colleges, skilling in medical devices

A mission will be launched to eliminate sickle cell anaemia in the country by 2047, says Finance Minister

Strong US sales momentum may drive further gains for Zydus Lifesciences

Market share gains in the Indian market and margin expansion are other positives

Glenmark Pharmaceuticals launches drug to treat heart failure in India

Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF

Glenmark launches generic version of diuretic Bumetanide injection

Glenmark Pharmaceuticals Ltd on Tuesday said its US arm has launched its generic version of diuretic Bumetanide injection. In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials. These are the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC, it added. The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan said. The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.

Drug firm Gland Pharma to fully acquire Europe-based Cenexi Group

Drug firm Gland Pharma on Friday said it has inked a pact with FPCI Sino French Midcap Fund to acquire 100 per cent stake in Europe-based Cenexi Group. Gland Pharma International PTE, a Singapore-based wholly owned subsidiary of the company, has entered into a share purchase agreement with FPCI Sino French Midcap Fund to fully acquire stake in Cenexi pursuant to the terms of the put option agreement inked in November last year. On November 29, 2022, the Hyderabad-based drug contract development and manufacturing company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to EUR 120 million (around Rs 1,015 crore), marking its foray into the international markets. Under the put option, an entity gets the right not obligation to sell a specified amount or stake at a predetermined price. Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical ...

BDR Pharma prostate cancer drug at 1/3rd of innovator brand price

The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000

Syrup deaths in Uzbekistan: Pharmexcil suspends Marion Biotech's membership

Co grew rapidly in the last four-five years; primarily makes cold medication

Cough syrup-linked deaths: Manufacturing activities stopped at Noida firm

All manufacturing activities at Marion Biotech's Noida unit have been stopped in view of reports of contamination of its cough syrup, Dok-1 Max, Union Health Minister Mansukh Mandaviya said on Friday. Further investigation in connection with the death of 18 children in Uzbekistan allegedly linked to the cough syrup is going on, the minister said in a tweet. "Following inspection by @CDSCO_INDIA_INF team in view of reports of contamination in cough syrup Dok1 Max, all manufacturing activities of Marion Biotech at NOIDA unit have been stopped yesterday night, while further investigation is ongoing," Mandaviya said. Government sources said Uzbek officials reached out to India on Thursday night regarding the cough syrup-linked deaths and seeking a thorough probe in the matter. A legal representative of the company had said on Thursday that the manufacturing of Dok-1 Max has stopped "for now". Marion Biotech does not sell Dok-1 Max in India and its only export has been to Uzbekistan, a

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

Corporate India gears up to hedge China supply risk amid Covid surge

The sectors in India that import from China include pharmaceutical (pharma), automotive (auto), textile, engineering, and electronic goods

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

CDSCO, states begin joint checks of drug-making units across India

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

Eyestem to start first trial in India to treat age-related blindness

The first nine patients that they will inject would be legally blind, as they have to prove safety first

Drug, medical services firm PharmEasy may lay off hundreds of employees

The company has a total workforce of about 1500

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Lessons from Covid: Pharma firms turn attention to adult vaccination

Vaccine companies have warmed up to the idea of adult vaccines for other diseases such as pneumonia, flu and shingles as well

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said